Pharmacogenetic Testing - (0500) — MM 0500 | CIGNA Coverage Update

Cigna modified MM 0500, its pharmacogenetic testing coverage policy, effective October 16, 2025. Here's what billing teams need to do.

Cigna Healthcare updated Coverage Policy MM 0500 governing pharmacogenetic testing. This modification affects 38 CPT codes and one HCPCS code — spanning drug metabolism panels, psychiatric genomic analysis, oncology pharmacogenomics, and warfarin response testing. If your practice bills codes like 81418, 0347U–0350U, 0173U, 0345U, or G9143, review this policy before October 16, 2025.

Quick-Reference Table

Cigna Pharmacogenetic Testing Coverage Criteria and Medical Necessity Requirements 2025

The Cigna pharmacogenetic testing coverage policy under MM 0500 classifies every covered code as "Medically Necessary when criteria in the applicable section are met." That phrasing does real work. It means coverage is never automatic — it's conditional on documented clinical criteria at the time of billing.

Pharmacogenetic (PGx) testing examines gene variations in a patient's DNA to predict how that individual responds to specific medications. Cigna covers it when specific clinical conditions are satisfied. Without documentation proving those conditions, the claim is a denial waiting to happen.

The policy covers a wide range of test types: single-gene drug metabolism assays (like CYP2C19 via CPT 81225 or SLCO1B1 via CPT 81328), multi-gene panels for psychiatry (0173U, 0175U, 0345U, 0411U, 0423U, 0476U, 0477U), whole-blood genomic panels covering 40+ genes (CPT 0516U), and warfarin response testing (CPT 0030U, 81355, G9143). The breadth is significant — and so is the documentation burden.

Psychiatric PGx billing draws the most scrutiny here. Codes like 0173U, 0175U, 0345U, 0392U, 0411U, 0419U, 0423U, 0437U, 0476U, and 0477U all cover depression, anxiety, and ADHD indications. If your psychiatry or behavioral health practice orders multi-gene panels routinely, confirm each order links back to a documented, covered indication before the test is performed. MM 0500 does not specify prior authorization requirements — verify Cigna's current PA requirements separately before billing these panels.

For oncology, CPT codes 0460U and 0461U cover pharmacogenomic SNP genotyping. CPT 0456U covers rheumatoid arthritis gene expression testing for 19 genes. These are narrower indications — make sure your documentation matches the specific condition, not just "oncology" broadly.

Warfarin pharmacogenetic testing has multiple code pathways: 0030U (targeted sequence analysis), 81355 (VKORC1 analysis), and G9143 (any method, any number of specimens). All three require medical necessity support. If you bill more than one for the same patient encounter, expect a claim denial without strong justification in the record.

For G6PD testing (CPT 81247) and IFNL3 testing (CPT 81283), the clinical use cases are specific — hemolytic anemia risk and interferon drug response, respectively. ICD-10 codes G35.A- and G35.D (multiple sclerosis) appear in MM 0500. The source does not explain the clinical context — verify the applicable section criteria directly before billing PGx under these diagnosis codes.

Cigna Pharmacogenetic Testing Exclusions and Non-Covered Indications

The policy data does not list specific experimental or not-covered designations for individual codes. Every code in MM 0500 carries the same conditional coverage label.

That said, the policy explicitly redirects oncology and hematology PGx to a separate coverage policy: "Molecular and Proteomic Diagnostic Testing for Hematology and Oncology Indications." If your lab bills for oncologic PGx beyond CPT 0460U and 0461U, MM 0500 alone does not cover you. Pull that companion policy and verify your oncology PGx codes against both documents before October 16, 2025.

The real exposure here is not a blanket exclusion — it's conditional coverage without documentation. Claims that lack clear medical necessity support at the time of billing are functionally non-covered. Treat undocumented PGx orders as denials in progress.

Coverage Indications at a Glance

Cigna Pharmacogenetic Testing Billing Guidelines and Action Items 2025

If you're unsure how this modification changes your specific payer mix or panel ordering patterns, talk to your compliance officer before October 16, 2025. The conditional coverage language in MM 0500 means the risk is in the documentation gap — not the test itself.

CPT, HCPCS, and ICD-10 Codes for Pharmacogenetic Testing Under MM 0500

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Covered HCPCS Codes (When Medical Necessity Criteria Are Met)

Key ICD-10-CM Diagnosis Codes